Human LOXL2 knockout HeLa cell line
Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and Insertion of the selection cassette in exon 4
Sanger Seq - LOXL2 knockout HeLa
Sanger Seq - LOXL2 knockout HeLa
Sanger Seq - LOXL2 knockout HeLa
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Cell line: HeLa
Number of cells: 1x106 cells/vial, 1 mL
Cell type: Epithelial
Tissue type: Cervix
Disease: Adenocarcinoma
Organism: Human
Gender: Female
Antibiotic resistance: Puromycin 1 µg/ml
Adherent: Yes
STR analysis: Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10
Passage number: <20
Biosafety level: 2
Viability: ~90%
Mycoplasma free: Yes
Storage: Shipped on dry ice. Store in liquid nitrogen.
Buffer constituents: 8.7% DMSO, 2% cellulose, methyl ether
Antibody selection and enhanced validation strategies to improve reproducibility
Antibody reproducibility remains an important issue across the Life Sciences industry. Abcam has been raising industry quality standards to help researchers address this challenge, using the best-available antibody formats and validation techniques. In this video, Alejandra Solache, VP New Product Development at Abcam, shares her insights on selecting the right validated antibody for improved experimental reproducibility.
